XML 38 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Organization, Description of Business and Summary of Significant Accounting Policies (Details Textual)
3 Months Ended 6 Months Ended 12 Months Ended
May 13, 2020
USD ($)
May 07, 2019
USD ($)
$ / shares
shares
Dec. 28, 2018
USD ($)
Jun. 30, 2020
USD ($)
$ / shares
Jun. 30, 2019
USD ($)
$ / shares
Mar. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
$ / shares
Jun. 30, 2019
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Number of Operating Segments             1    
Number of Disease Areas with Genomic Testing       4     4    
Stock Issued During Period, Shares, New Issues (in shares) | shares   6,325,000              
Sale of Stock, Price Per Share (in dollars per share) | $ / shares   $ 23.25              
Proceeds from Issuance of Common Stock   $ 137,800,000         $ 0 $ 137,848,000  
Payments of Stock Issuance Costs   $ 9,200,000              
Restricted Cash and Cash Equivalents, Noncurrent, Total       $ 603,000     603,000   $ 603,000
Revenue from Contract with Customer, Excluding Assessed Tax, Total       20,704,000 $ 30,136,000   51,826,000 59,665,000  
Operating Income (Loss), Total       $ (11,051,000) $ (3,100,000)   $ (23,251,000) $ (5,167,000)  
Earnings Per Share, Basic and Diluted, Total (in dollars per share) | $ / shares       $ (0.22) $ (0.05)   $ (0.45) $ (0.10)  
Inventory Write-down             $ 1,088,000 $ 0  
Loxo Oncology Inc [Member] | Collaborative Arrangement [Member]                  
Contract Agreement, Term (Year)             1 year    
Contract Agreement, Automatic Renewal Term (Year)             1 year    
Contract Agreement, Termination Period (Day)             90 days    
Contract with Customer, Liability, Revenue Recognized             $ 0   0
Johnson and Johnson Services Inc JJSI [Member] | Collaborative Arrangement [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total       $ 1,300,000          
Contract with Customer, Liability, Revenue Recognized             0   0
Collaborative Agreement, Amount     $ 7,000,000.0            
Collaborative Agreement, Contingent Receivable Amount     $ 13,000,000.0            
Collaborative Agreement, Period of Payments After First Commercial (Year)     10 years            
Collaborative Agreement, Fee Percentage of Cash Collections     1.00%            
Accounts Receivable, after Allowance for Credit Loss, Total       500,000     500,000   2,000,000.0
Acerta Pharma BV [Member] | Collaborative Arrangement [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total       200,000     400,000    
Accounts Receivable, after Allowance for Credit Loss, Total       1,400,000     1,400,000    
Revenue from Achievement of Development Milestones       1,000,000.0          
CareDx [Member] | Collaborative Arrangement [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total       1,000,000.0          
Accounts Receivable, after Allowance for Credit Loss, Total       0     0    
Contract with Customer, Liability, Total $ 1,000,000.0     0     0    
Commercial Development Agreement, Maximum Payments Receivable from Counter Party Upon Achievement of Milestones 4,500,000                
Value of Support Services to Counter Party $ 500,000                
Testing [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total       15,212,000 $ 26,686,000   42,203,000 52,075,000  
Testing [Member] | Cost of Sales [Member] | COVID 19 Pandemic [Member]                  
Inventory Write-down       1,100,000          
Testing [Member] | Revenue Recognition [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total       900,000 100,000   700,000 800,000  
Operating Income (Loss), Total       $ 900,000 $ 100,000   $ 700,000 $ 800,000  
Earnings Per Share, Basic and Diluted, Total (in dollars per share) | $ / shares       $ 20,000.00 $ 0.01   $ 0.01 $ 0.02  
Collaborative [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total       $ 0     $ 0    
Product [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total       1,713,000 $ 0   5,122,000 $ 0  
Product [Member] | Loxo Oncology Inc [Member] | Collaborative Arrangement [Member]                  
Contract with Customer, Liability, Revenue Recognized         0 $ 90,000 0    
Service [Member] | Loxo Oncology Inc [Member] | Collaborative Arrangement [Member]                  
Contract with Customer, Liability, Revenue Recognized       $ 250,000     $ 500,000    
Percepta v2 [Member] | Johnson and Johnson Services Inc JJSI [Member] | Collaborative Arrangement [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total         1,200,000     5,000,000.0  
Fulfillment of Obligations Relating to Percepta v.2 Development Milestones [Member] | Johnson and Johnson Services Inc JJSI [Member] | Collaborative Arrangement [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total         $ 2,000,000.0        
Overnight Reverse Repurchase Agreements [Member]                  
Cash Equivalents, Percentage Collateralized by US Treasury and Agency Securities       102.00%     102.00%    
Cash Equivalents, at Carrying Value, Total       $ 0     $ 0    
Collateral for Irrevocable Standby Letter of Credit [Member]                  
Restricted Cash and Cash Equivalents, Noncurrent, Total       $ 603,000     $ 603,000   $ 603,000
Over-Allotment Option [Member]                  
Stock Issued During Period, Shares, New Issues (in shares) | shares   825,000              
Revision of Prior Period, Adjustment [Member]                  
Increase (Decrease) in Operating Capital, Total               $ 431,000